Institut Gustave Roussy

Centre National De La Recherche Scientifique

Istituto Europeo Di Oncologia (Ieo)

Cisbio Bioassays

Fabrice Andre

Laurence Zitvogel

Gérard Mathis

Hervé Bazin

Patrick Garnero

Jean-Christophe Sabourin

Philippe Vielh

Stefan Michiels

Suzette Delaloge

Marc Spielmann

Philippe Dessen

Michiels Stefan

Mohamed Amine Bayar

Carmen Criscitiello

Giuseppe Curigliano

The present invention relates to the use of the value of the expression of at least one gene selected from the group comprising: GBP 1 gene, HLF gene, CXCL13 gene and SULT1E1 gene, for the estimation of prognosis of distant relapse-free survival or overall survival of a patient with triple negative breast cancer (TNBC) having received a neoadjuvant chemotherapy (NACT).

Use of the expression of specific genes for the prognosis of patients with triple negative breast cancer

The present invention relates generally to the fields of genetics and medicine. More specifically, the present invention relates to improved methods of treating cancers using a TLR3 agonist, by assessing the expression of a TLR3 receptor by cancer cells.

Treatment of cancer using TLR3 agonists

The invention relates to the use of a multiplicity of polynucleotide probe sets, the multiplicity of polynucleotide probe sets consisting in a combination of pools of polynucleotide probe sets, each polynucleotide probe set containing at least one polynucleotide probe chosen among a library of nucleic acid sequences, the polynucleotide probes involved in the combination of pools of polynucleotide probe sets of the multiplicity of polynucleotide probe sets being such that each polynucleotide probe specifically hybridizes with one gene, and/or at least one of its variants when present, for determining the variation of expression at least 12 genes, and their variants when present, in order to diagnose the benign or malignant state of a breast tumor.

Molecular in vitro diagnosis of breast cancer

Growing community of inventors

Sceaux, France

Fabrice Andre